Skip to main content
Top
Published in: Current Geriatrics Reports 3/2018

01-09-2018 | Pulmonology and Respiratory Care (D Breen, Section Editor)

Muscle Wasting in the Hospitalised COPD Patients—How Can it Be Prevented and Treated?

Authors: Tara Cahill, Mohammed Ahmed

Published in: Current Geriatrics Reports | Issue 3/2018

Login to get access

Abstract

Purpose of Review

COPD exacerbations are widely recognised as a significant cause of mortality and morbidity through their impact on respiratory function but their effect on skeletal muscle function and mass receives less attention. In this article, we review the association of this entity with COPD, the potential contributing factors, and the evidence behind the interventions available to manage this condition with a focus on the elderly population.

Recent Findings

In patients with COPD, there has been a paradigm shift from the focus on body weight and mass index to a more detailed assessment of the loss of muscle mass and function defined as sarcopaenia. Factors that can potentially lead to sarcopaenia has been the subject of multiple basic science and translational research studies. Interventions that have been proven to be associated with clinically significant outcomes in COPD patients include early mobilisation, inpatient exercise programmes, early pulmonary rehabilitation, and nutritional interventions. Prolonged courses of steroids following an acute exacerbation are non-beneficial and can lead to loss of muscle function.

Summary

Multiple factors can potentially contribute to sarcopaenia among patients admitted with COPD exacerbations and should be identified early and treated in a multidisciplinary setting. Nutritional interventions, early mobilisation, and limitation of systemic steroid prescribing are simple and effective interventions that should be utilised.
Literature
1.
go back to reference • Biolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. Clin Nutr Edinb Scotl. 2014;33(5):737–48. Provides a very detailed yet succinct description of sarcopaenia and its causative factors. CrossRef • Biolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. Clin Nutr Edinb Scotl. 2014;33(5):737–48. Provides a very detailed yet succinct description of sarcopaenia and its causative factors. CrossRef
2.
go back to reference Ståhl E, Lindberg A, Jansson S-A, Rönmark E, Svensson K, Andersson F, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes. 2005;3:56.CrossRefPubMedPubMedCentral Ståhl E, Lindberg A, Jansson S-A, Rönmark E, Svensson K, Andersson F, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes. 2005;3:56.CrossRefPubMedPubMedCentral
3.
go back to reference Akinbami LJ, Liu X. Chronic obstructive pulmonary disease among adults aged 18 and over in the United States, 1998–2009. NCHS Data Brief. 2011;63:1–8. Akinbami LJ, Liu X. Chronic obstructive pulmonary disease among adults aged 18 and over in the United States, 1998–2009. NCHS Data Brief. 2011;63:1–8.
4.
go back to reference Maleki-Yazdi MR, Kelly SM, Lam SY, Marin M, Barbeau M, Walker V. The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada. Can Respir J. 2012;19(5):319–24.CrossRefPubMedPubMedCentral Maleki-Yazdi MR, Kelly SM, Lam SY, Marin M, Barbeau M, Walker V. The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada. Can Respir J. 2012;19(5):319–24.CrossRefPubMedPubMedCentral
5.
go back to reference Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. Chest. 2015;147(1):31–45.CrossRefPubMed Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. Chest. 2015;147(1):31–45.CrossRefPubMed
6.
go back to reference Bustacchini S, Chiatti C, Furneri G, Lattanzio F, Mantovani LG. The economic burden of chronic obstructive pulmonary disease in the elderly: results from a systematic review of the literature. Curr Opin Pulm Med. 2011;17(Suppl 1):S35–41.CrossRefPubMed Bustacchini S, Chiatti C, Furneri G, Lattanzio F, Mantovani LG. The economic burden of chronic obstructive pulmonary disease in the elderly: results from a systematic review of the literature. Curr Opin Pulm Med. 2011;17(Suppl 1):S35–41.CrossRefPubMed
8.
go back to reference Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R, IMPAC Study Group. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004;59(5):387–395. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R, IMPAC Study Group. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004;59(5):387–395.
9.
go back to reference Donaldson GC, Wedzicha JA. COPD exacerbations .1: epidemiology. Thorax 2006;61(2):164–168. Donaldson GC, Wedzicha JA. COPD exacerbations .1: epidemiology. Thorax 2006;61(2):164–168.
10.
go back to reference Perera PN, Armstrong EP, Sherrill DL, Skrepnek GH. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD. 2012;9(2):131–41.CrossRefPubMed Perera PN, Armstrong EP, Sherrill DL, Skrepnek GH. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD. 2012;9(2):131–41.CrossRefPubMed
11.
go back to reference Miravitlles M, García-Polo C, Domenech A, Villegas G, Conget F, de la Roza C. Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease. Lung. 2013;191(5):523–30.CrossRefPubMed Miravitlles M, García-Polo C, Domenech A, Villegas G, Conget F, de la Roza C. Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease. Lung. 2013;191(5):523–30.CrossRefPubMed
12.
go back to reference Singer JP, Peterson ER, Snyder ME, Katz PP, Golden JA, D’Ovidio F, et al. Body composition and mortality after adult lung transplantation in the United States. Am J Respir Crit Care Med. 2014;190(9):1012–21.CrossRefPubMedPubMedCentral Singer JP, Peterson ER, Snyder ME, Katz PP, Golden JA, D’Ovidio F, et al. Body composition and mortality after adult lung transplantation in the United States. Am J Respir Crit Care Med. 2014;190(9):1012–21.CrossRefPubMedPubMedCentral
13.
go back to reference Xue Q-L, Walston JD, Fried LP, Beamer BA. Prediction of risk of falling, physical disability, and frailty by rate of decline in grip strength: the women’s health and aging study. Arch Intern Med. 2011;171(12):1119–21.CrossRefPubMed Xue Q-L, Walston JD, Fried LP, Beamer BA. Prediction of risk of falling, physical disability, and frailty by rate of decline in grip strength: the women’s health and aging study. Arch Intern Med. 2011;171(12):1119–21.CrossRefPubMed
14.
go back to reference Dufour AB, Hannan MT, Murabito JM, Kiel DP, McLean RR. Sarcopenia definitions considering body size and fat mass are associated with mobility limitations: the Framingham Study. J Gerontol A Biol Sci Med Sci. 2013;68(2):168–74.CrossRefPubMed Dufour AB, Hannan MT, Murabito JM, Kiel DP, McLean RR. Sarcopenia definitions considering body size and fat mass are associated with mobility limitations: the Framingham Study. J Gerontol A Biol Sci Med Sci. 2013;68(2):168–74.CrossRefPubMed
15.
go back to reference Janssen I. Evolution of sarcopenia research. Appl Physiol Nutr Metab Physiol Appl Nutr Metab. 2010;35(5):707–12.CrossRef Janssen I. Evolution of sarcopenia research. Appl Physiol Nutr Metab Physiol Appl Nutr Metab. 2010;35(5):707–12.CrossRef
16.
go back to reference Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. Chest. 2006;129(3):536–44.CrossRefPubMed Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. Chest. 2006;129(3):536–44.CrossRefPubMed
17.
go back to reference Garcia-Aymerich J, Farrero E, Félez MA, Izquierdo J, Marrades RM, Antó JM, Estudi del Factors de Risc d’Agudització de la MPOC investigators. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003;58(2):100–105. Garcia-Aymerich J, Farrero E, Félez MA, Izquierdo J, Marrades RM, Antó JM, Estudi del Factors de Risc d’Agudització de la MPOC investigators. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003;58(2):100–105.
18.
go back to reference Cesari M, Pedone C, Chiurco D, Cortese L, Conte ME, Scarlata S, et al. Physical performance, sarcopenia and respiratory function in older patients with chronic obstructive pulmonary disease. Age Ageing. 2012;41(2):237–41.CrossRefPubMed Cesari M, Pedone C, Chiurco D, Cortese L, Conte ME, Scarlata S, et al. Physical performance, sarcopenia and respiratory function in older patients with chronic obstructive pulmonary disease. Age Ageing. 2012;41(2):237–41.CrossRefPubMed
19.
go back to reference • da Rocha Lemos Costa TM, Costa FM, Moreira CA, Rabelo LM, Boguszewski CL, Borba VZC. Sarcopenia in COPD: relationship with COPD severity and prognosis. J Bras Pneumol Publicacao Of Soc Bras Pneumol E Tisilogia. 2015;41(5):415–21. This paper evaluates the prevalence of sarcopaenia in COPD patients and also confirms that sarcopaenia correlates with a worse prognosis in COPD. • da Rocha Lemos Costa TM, Costa FM, Moreira CA, Rabelo LM, Boguszewski CL, Borba VZC. Sarcopenia in COPD: relationship with COPD severity and prognosis. J Bras Pneumol Publicacao Of Soc Bras Pneumol E Tisilogia. 2015;41(5):415–21. This paper evaluates the prevalence of sarcopaenia in COPD patients and also confirms that sarcopaenia correlates with a worse prognosis in COPD.
20.
go back to reference de Morton NA, Keating JL, Jeffs K. Exercise for acutely hospitalised older medical patients. Cochrane Database Syst Rev. 2007;1:CD005955. de Morton NA, Keating JL, Jeffs K. Exercise for acutely hospitalised older medical patients. Cochrane Database Syst Rev. 2007;1:CD005955.
22.
go back to reference Rodriguez DA, Rodo-Pin A, Guerrero M, Coll R, Huerta A, Soler N, et al. Impact of step exercises as an early intervention during COPD exacerbation. Eur Respir J. 2016;48(suppl 60):PA2061. Rodriguez DA, Rodo-Pin A, Guerrero M, Coll R, Huerta A, Soler N, et al. Impact of step exercises as an early intervention during COPD exacerbation. Eur Respir J. 2016;48(suppl 60):PA2061.
23.
go back to reference Donaldson GC, Seemungal TAR, Patel IS, Bhowmik A, Wilkinson TMA, Hurst JR, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128(4):1995–2004.CrossRefPubMed Donaldson GC, Seemungal TAR, Patel IS, Bhowmik A, Wilkinson TMA, Hurst JR, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128(4):1995–2004.CrossRefPubMed
24.
go back to reference Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994;150(5 Pt 1):1453–5.CrossRefPubMed Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994;150(5 Pt 1):1453–5.CrossRefPubMed
25.
26.
go back to reference Ferrando AA, Stuart CA, Sheffield-Moore M, Wolfe RR. Inactivity amplifies the catabolic response of skeletal muscle to cortisol. J Clin Endocrinol Metab. 1999;84(10):3515–21.PubMed Ferrando AA, Stuart CA, Sheffield-Moore M, Wolfe RR. Inactivity amplifies the catabolic response of skeletal muscle to cortisol. J Clin Endocrinol Metab. 1999;84(10):3515–21.PubMed
27.
go back to reference Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol. 1985;76(2 Pt 1):234–42.CrossRefPubMed Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol. 1985;76(2 Pt 1):234–42.CrossRefPubMed
28.
go back to reference Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med. 1994;150(1):11–6.CrossRefPubMed Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med. 1994;150(1):11–6.CrossRefPubMed
29.
go back to reference Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223–31.CrossRefPubMed Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223–31.CrossRefPubMed
30.
go back to reference Vermeeren M a P, Creutzberg EC, Schols AMWJ, Postma DS, Pieters WR, Roldaan AC, et al. Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med. 2006;100(8):1349–55.CrossRefPubMed Vermeeren M a P, Creutzberg EC, Schols AMWJ, Postma DS, Pieters WR, Roldaan AC, et al. Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med. 2006;100(8):1349–55.CrossRefPubMed
31.
go back to reference Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1791–7.CrossRefPubMed Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1791–7.CrossRefPubMed
32.
go back to reference Schols AMWJ, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005;82(1):53–9.CrossRefPubMed Schols AMWJ, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005;82(1):53–9.CrossRefPubMed
33.
go back to reference Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–35.CrossRefPubMed Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–35.CrossRefPubMed
34.
go back to reference Del Fabbro E, Parsons H, Warneke CL, Pulivarthi K, Litton JK, Dev R, et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist. 2012;17(10):1240–5.CrossRefPubMedPubMedCentral Del Fabbro E, Parsons H, Warneke CL, Pulivarthi K, Litton JK, Dev R, et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist. 2012;17(10):1240–5.CrossRefPubMedPubMedCentral
35.
go back to reference Muscaritoli M, Anker SD, Argilés J, Aversa Z, Bauer JM, Biolo G, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr Edinb Scotl. 2010;29(2):154–9.CrossRef Muscaritoli M, Anker SD, Argilés J, Aversa Z, Bauer JM, Biolo G, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr Edinb Scotl. 2010;29(2):154–9.CrossRef
36.
go back to reference Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M, European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39(4):412–423. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M, European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39(4):412–423.
37.
go back to reference Woo J, Leung J, Morley JE. Validating the SARC-F: a suitable community screening tool for sarcopenia? J Am Med Dir Assoc. 2014;15(9):630–4.CrossRefPubMed Woo J, Leung J, Morley JE. Validating the SARC-F: a suitable community screening tool for sarcopenia? J Am Med Dir Assoc. 2014;15(9):630–4.CrossRefPubMed
38.
go back to reference Metter EJ, Conwit R, Tobin J, Fozard JL. Age-associated loss of power and strength in the upper extremities in women and men. J Gerontol A Biol Sci Med Sci. 1997;52(5):B267–76.CrossRefPubMed Metter EJ, Conwit R, Tobin J, Fozard JL. Age-associated loss of power and strength in the upper extremities in women and men. J Gerontol A Biol Sci Med Sci. 1997;52(5):B267–76.CrossRefPubMed
39.
40.
go back to reference Joseph A-M, Adhihetty PJ, Buford TW, Wohlgemuth SE, Lees HA, Nguyen LM-D, et al. The impact of aging on mitochondrial function and biogenesis pathways in skeletal muscle of sedentary high- and low-functioning elderly individuals. Aging Cell. 2012;11(5):801–9.CrossRefPubMedPubMedCentral Joseph A-M, Adhihetty PJ, Buford TW, Wohlgemuth SE, Lees HA, Nguyen LM-D, et al. The impact of aging on mitochondrial function and biogenesis pathways in skeletal muscle of sedentary high- and low-functioning elderly individuals. Aging Cell. 2012;11(5):801–9.CrossRefPubMedPubMedCentral
41.
go back to reference Bua EA, McKiernan SH, Wanagat J, McKenzie D, Aiken JM. Mitochondrial abnormalities are more frequent in muscles undergoing sarcopenia. J Appl Physiol Bethesda Md 1985. 2002;92(6):2617–24. Bua EA, McKiernan SH, Wanagat J, McKenzie D, Aiken JM. Mitochondrial abnormalities are more frequent in muscles undergoing sarcopenia. J Appl Physiol Bethesda Md 1985. 2002;92(6):2617–24.
Metadata
Title
Muscle Wasting in the Hospitalised COPD Patients—How Can it Be Prevented and Treated?
Authors
Tara Cahill
Mohammed Ahmed
Publication date
01-09-2018
Publisher
Springer US
Published in
Current Geriatrics Reports / Issue 3/2018
Electronic ISSN: 2196-7865
DOI
https://doi.org/10.1007/s13670-018-0245-1

Other articles of this Issue 3/2018

Current Geriatrics Reports 3/2018 Go to the issue

Nutrition, Obesity and Diabetes (L Falque-Madrid and H Florez, Section Editors

Public Health Nutrition Programs for the Elderly: Epidemiological Basis

Pulmonology and Respiratory Care (D Breen, Section Editor)

Malignant Pleural Effusions—Personalised Management

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.